Information Provided By: 
Fly News Breaks for February 9, 2016
BSX
Feb 9, 2016 | 07:24 EDT
After the Centers for Medicare and Medicaid Services released its coverage determination for Boston Scientific's Watchman device, Stifel says the decision is "very positive," and should "bode well" for a strong U.S. release of the device. The firm thinks the decision will improve investor sentiment towards the company. It keeps a $22 price target and Buy rating on the stock.
News For BSX From the Last 2 Days
BSX
Apr 24, 2024 | 16:20 EDT
BSX
Apr 24, 2024 | 13:53 EDT
Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.
BSX
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BSX
Apr 24, 2024 | 07:03 EDT
BSX
Apr 24, 2024 | 07:01 EDT
BSX
Apr 24, 2024 | 07:00 EDT
BSX
Apr 23, 2024 | 13:18 EDT
